These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 15671616)

  • 1. Risk of alveolar hemorrhage in patients with primary pulmonary hypertension--anticoagulation and epoprostenol therapy.
    Ogawa A; Matsubara H; Fujio H; Miyaji K; Nakamura K; Morita H; Saito H; Kusano KF; Emori T; Date H; Ohe T
    Circ J; 2005 Feb; 69(2):216-20. PubMed ID: 15671616
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Acute circulatory failure caused by primary pulmonary hypertension or pulmonary embolism].
    Meyer G; Sanchez O
    Rev Mal Respir; 2000 Feb; 17(1):51-65. PubMed ID: 10756556
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-coagulation complications in pregnancies with severe pulmonary arterial hypertension.
    Herrero T; Martin E; Poch DS; Roeder HA
    J Matern Fetal Neonatal Med; 2018 May; 31(9):1209-1213. PubMed ID: 28353362
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intravenous epoprostenol in inoperable chronic thromboembolic pulmonary hypertension.
    Cabrol S; Souza R; Jais X; Fadel E; Ali RH; Humbert M; Dartevelle P; Simonneau G; Sitbon O
    J Heart Lung Transplant; 2007 Apr; 26(4):357-62. PubMed ID: 17403477
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Paradoxical effect of prostacyclin infusion in a patient with primary pulmonary hypertension-a case report.
    Younger JR; Lui CY
    Angiology; 2004; 55(3):341-4. PubMed ID: 15156270
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Education of patients treated with a continuous epoprostenol infusion for pulmonary hypertension].
    Marlier D
    Soins; 2006 May; (705 Suppl):S7-12. PubMed ID: 16771257
    [No Abstract]   [Full Text] [Related]  

  • 7. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension.
    Barst RJ; Rubin LJ; Long WA; McGoon MD; Rich S; Badesch DB; Groves BM; Tapson VF; Bourge RC; Brundage BH; Koerner SK; Langleben D; Keller CA; Murali S; Uretsky BF; Clayton LM; Jöbsis MM; Blackburn SD; Shortino D; Crow JW;
    N Engl J Med; 1996 Feb; 334(5):296-301. PubMed ID: 8532025
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Survival in primary pulmonary hypertension: the impact of epoprostenol therapy.
    McLaughlin VV; Shillington A; Rich S
    Circulation; 2002 Sep; 106(12):1477-82. PubMed ID: 12234951
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Twin pregnancy in a woman on long-term epoprostenol therapy for primary pulmonary hypertension. A case report.
    Badalian SS; Silverman RK; Aubry RH; Longo J
    J Reprod Med; 2000 Feb; 45(2):149-52. PubMed ID: 10710749
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reduction in pulmonary vascular resistance with long-term epoprostenol (prostacyclin) therapy in primary pulmonary hypertension.
    McLaughlin VV; Genthner DE; Panella MM; Rich S
    N Engl J Med; 1998 Jan; 338(5):273-7. PubMed ID: 9445406
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The influence of continuous intravenous prostacyclin therapy for primary pulmonary hypertension on the timing and outcome of transplantation.
    Conte JV; Gaine SP; Orens JB; Harris T; Rubin LJ
    J Heart Lung Transplant; 1998 Jul; 17(7):679-85. PubMed ID: 9703232
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Primary pulmonary hypertension: new treatment options].
    Madan S; Boonstra A; Berger RM
    Ned Tijdschr Geneeskd; 2001 Sep; 145(38):1836-42. PubMed ID: 11593786
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact on survival of warfarin in patients with pulmonary arterial hypertension receiving subcutaneous treprostinil.
    Ascha M; Zhou X; Rao Y; Minai OA; Tonelli AR
    Cardiovasc Ther; 2017 Oct; 35(5):. PubMed ID: 28643420
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of prostacyclin (epoprostenol) as anticoagulant in continuous renal replacement therapies: efficacy, security and cost analysis.
    Gainza FJ; Quintanilla N; Pijoan JI; Delgado S; Urbizu JM; Lampreabe I
    J Nephrol; 2006; 19(5):648-55. PubMed ID: 17136695
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Clinico-hemodynamic study and treatment of 44 patients with primary pulmonary hypertension].
    Roman A; Rodés-Cabau J; Lara B; Bravo C; Monforte V; Pallissa E; Domingo E; Morell F
    Med Clin (Barc); 2002 Jun; 118(20):761-6. PubMed ID: 12049690
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival.
    Sitbon O; Humbert M; Nunes H; Parent F; Garcia G; Hervé P; Rainisio M; Simonneau G
    J Am Coll Cardiol; 2002 Aug; 40(4):780-8. PubMed ID: 12204511
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pulmonary edema during acute infusion of epoprostenol in a patient with pulmonary hypertension and limited scleroderma.
    Farber HW; Graven KK; Kokolski G; Korn JH
    J Rheumatol; 1999 May; 26(5):1195-6. PubMed ID: 10332990
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A survey of diagnostic practices and the use of epoprostenol in patients with primary pulmonary hypertension.
    Robbins IM; Christman BW; Newman JH; Matlock R; Loyd JE
    Chest; 1998 Nov; 114(5):1269-75. PubMed ID: 9824000
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Therapeutic management of primary pulmonary hypertension].
    Chaouat A; Weitzenblum E
    Presse Med; 2002 Feb; 31(7):320-8. PubMed ID: 11899690
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vasopressin during spinal anesthesia in a patient with primary pulmonary hypertension treated with intravenous epoprostenol.
    Braun EB; Palin CA; Hogue CW
    Anesth Analg; 2004 Jul; 99(1):36-37. PubMed ID: 15281498
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.